Caption Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$770K Buy
+20,000
New +$739K ﹤0.01% 1096
2025
Q4
Sell
-176,064
Closed -$4.95M 1639
2025
Q3
$2.53M Sell
176,064
-261,164
-60% -$3.09M 0.02% 753
2025
Q2
$3.14M Buy
+437,228
New +$2.42M 0.03% 564
2025
Q1
Sell
-112,100
Closed -$874K 1602
2024
Q4
$874K Buy
+112,100
New +$1.12M 0.01% 960
2024
Q2
Sell
-9,400
Closed -$63.2K 1209
2024
Q1
$63.2K Buy
+9,400
New +$58.1K ﹤0.01% 1083
2022
Q3
Sell
-23,000
Closed -$207K 1550
2022
Q2
$207K Buy
+23,000
New +$157K ﹤0.01% 1228

Other funds holding COGT

Caption Management's COGT Position: Q1 2026 in Review

Caption Management opened a new position in Cogent Biosciences (COGT) in Q1 2026: 20,000 shares worth $770K. The stake represents ﹤0.01% of the portfolio and ranks #1096 among its holdings. This is a return to the name: Caption Management previously reported a position in COGT as recently as Q3 2025.

Caption Management first reported a position in COGT in Q2 2022 and has held it in 6 quarters since. The position peaked at $3.14M in Q2 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Caption Management held 20,000 shares of Cogent Biosciences worth $770K as of Q1 2026.
  • Cogent Biosciences was a new Caption Management position in Q1 2026.
  • Cogent Biosciences made up ﹤0.01% of Caption Management's portfolio in Q1 2026, its #1096 holding.
  • Caption Management first reported a position in Cogent Biosciences in Q2 2022 and has held it in 6 quarters since.
  • Caption Management's Cogent Biosciences position peaked at $3.14M in Q2 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Caption Management's 13F filing for Q1 2026, filed 15 May 2026.